+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P10442(CBLIF Antibody) at dilution 1/220. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10442(CBLIF Antibody) at dilution 1/220. (Original magnification: ×200)    

  
  

**Background of CBLIF Antibody**

The CBLIF (Calcium-Binding Ligand Immunofluorescence) antibody is a specialized tool developed to detect and study calcium-binding proteins in biological systems. Calcium-binding proteins, such as calmodulin, S100 proteins, and annexins, play critical roles in cellular signaling, homeostasis, and regulation of enzymatic activities. The CBLIF antibody was designed to target specific epitopes on these proteins, enabling researchers to visualize their spatial distribution and expression levels in cells and tissues via immunofluorescence microscopy.

Its development stemmed from the need to investigate calcium-mediated pathways in diseases like cancer, neurodegenerative disorders, and cardiovascular conditions, where dysregulation of calcium signaling is often implicated. The antibody’s high specificity and affinity for calcium-bound conformations of target proteins make it particularly useful for studying dynamic intracellular calcium fluctuations.

CBLIF antibodies are typically produced using hybridoma technology or recombinant methods, ensuring consistency and scalability. They are widely employed in both basic research and clinical diagnostics, aiding in the identification of biomarkers and therapeutic targets. Recent advancements have also explored their use in multiplex imaging and single-cell analysis, enhancing precision in understanding calcium-dependent cellular mechanisms.

Overall, the CBLIF antibody serves as a vital reagent in calcium signaling research, bridging molecular insights with pathophysiological applications.